# Harbor Light Capital Partners

> Harbor Light Capital Partners is a VC fund backing Life Science. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Keene, United States
- Total investments: 12
- Last investment: Jul 2017
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/harbor-light-captial-partners
- Website: http://hlcp.com

Harbor Light Capital Partners is a VC fund in Keene focused on Life Science and Biotechnology. Harbor Light Capital Partners focuses on investments in the $1-$5 million range. Unlike institutional investment funds, we are not limited to traditional holding periods of 3 to 5 years. Therefore, we make decisions based on what is best for the growth and success of the business. Our investment flexibility, combined with our values, family legacyand management expertise, make us an attractive option for family-owned and emerging growth businesses seeking a long-term, value-adding partner.Early Stage Criteria: Technology or healthcare emphasis Innovative / disruptive technology Strong intellectual property position Large and attractive market opportunityGrowth Stage Criteria: Product and / or geographic growth potential Strong historical / projected revenue growth Profitable, or will be within 12 months Preference for recurring revenue streams Companies with passionate, loyal customers Lower middle market, $1M to $25M in revenues Exceptional management teams with proven entrepreneurial leadership and vision Harbor Light team can add significant value to the businessValue Generation Model Engage actively at the Board and operational level, and leverage Advisory Board expertise in finance, operations, marketing and technology Bring relationships and expertise for rapid growth; facilitate expansion through business networks Promote a long-term, relationship-based culture; develop and encourage business models built on “customer intimacy” Use financial leverage to improve risk/rewards profile; apply debt in prudent, strategic circumstances

## Contacts

5 contacts available for Harbor Light Capital Partners. Shizune tracks 3 team members at Harbor Light Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/harbor-light-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 17% |
| Biotechnology | 2 | 17% |
| Pet | 1 | 8% |
| SaaS | 1 | 8% |
| Sales | 1 | 8% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 42% |
| Series B | 3 | 25% |
| Funding Round | 1 | 8% |
| Private Equity | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Richard Upton | General Partner | 6 | — |
| Todd Warden | Managing Partner | 2 | — |
| Darby Kopp | General Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Carmell Cosmetics | Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle,shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage). | $4M | Series B | Jul 11, 2017 |  |
| Courtagen Life Sciences | Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts. | $20M | Private Equity | Jul 01, 2015 |  |
| Senet | Senet offers a low cost, long distance sensor network, and high-value SaaS applications on a subscription fee basis to help businesses make fact-based decisions. Senet's cost-effective, highly-scalable network enables companies to capitalize on opportunities in the rapidly growing Machine-to-Machine (M2M) Internet of Things (IoT) landscape. | $18M | Series A | Jun 22, 2015 |  |
| Carmell Cosmetics | Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle,shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage). | $681.5K | Series A | Jun 13, 2014 |  |
| Alcyone Lifesciences | Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reachingdiseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS.The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms. | $4M | Series B | Jan 15, 2014 |  |
| EnerTrac | EnerTrac saves fuel and reduces emissions by automating the measuring and monitoring processes of devices that have historically required manual reading and recording. EnerTrac innovative low frequency and low cost monitoring and communications network provides delivery companies with actionable data that makes their delivery schedules moretargeted and more efficient. EnerTrac technology facilitates machine to machine (M-2-M) communication and is currently being used to automate the monitoring of fuel oil and propane fuel tanks. The network that EnerTrac is establishing could ultimately be extended to monitor thermostats, flow meters, heating, ventilation and air conditioning systems. |  | Series A | Jul 18, 2013 |  |
| Draker | For over a decade, Draker has been providing monitoring, management and control solutions for commercial and utility solar energy systems. Draker’s range of products and services allows PV developers, owners and operators to increaseefficiency and optimize profitability of their solar assets. Draker’s turnkey commercial and end-to-end utilitysolutions include project-based services, field instrumentation, data collection and management, robust web applications withadvanced analytical tools, and public information displays. | $8M |  | Aug 22, 2012 |  |
| Courtagen Life Sciences | Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts. | $8M | Series B | Oct 18, 2011 |  |
| Draker | For over a decade, Draker has been providing monitoring, management and control solutions for commercial and utility solar energy systems. Draker’s range of products and services allows PV developers, owners and operators to increaseefficiency and optimize profitability of their solar assets. Draker’s turnkey commercial and end-to-end utilitysolutions include project-based services, field instrumentation, data collection and management, robust web applications withadvanced analytical tools, and public information displays. | $3M |  | Jun 29, 2011 |  |
| Carmell Cosmetics | Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle,shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage). | $2.4M | Series A | Apr 18, 2011 |  |

10 of 12 investments shown.

## Co-investors
- [BlueTree Allied Angels](https://shizune.co/investors/profile/bluetree-allied-angels) — VC Fund, 3 deals together
- Pittsburgh Life Sciences Greenhouse — VC Fund, 3 deals together
- [Austin Ventures](https://shizune.co/investors/profile/austin-ventures) — VC Fund, 2 deals together
- [City Light Capital](https://shizune.co/investors/profile/city-light-capital) — VC Fund, 2 deals together
- [FreshTracks Capital](https://shizune.co/investors/profile/freshtracks-capital) — VC Fund, 2 deals together
- [Activate Venture Partners](https://shizune.co/investors/profile/milestone-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Harbor Light Capital Partners invest in?

Harbor Light Capital Partners invests primarily in Life Science, Biotechnology and Pet startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Harbor Light Capital Partners?

Public channels for Harbor Light Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Harbor Light Capital Partners?

The team at Harbor Light Capital Partners includes Richard Upton (General Partner), Todd Warden (Managing Partner) and Darby Kopp (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co